Publications by authors named "Yuriko Uehara"

Claim this Profile
T
The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancreatic Cancer.
Yuki Eguchi, Yoichi Matsuo, Masaki Ishida, Yuriko Uehara, Saburo Sugita

Nutrients· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated genomic/epigenomic analysis stratifies subtypes of clear cell ovarian carcinoma, highlighting their cellular origin.
Akira Nishijima, Katsutoshi Oda, Kosei Hasegawa, Takahiro Koso, Kayo Asada, Yuriko Uehara

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[A Case of Intrahepatic Cholangiocarcinoma in Contact with the Gastroduodenal Anastomosis in Which Proton Beam Therapy Was Performed after Placement of an Absorbable Spacer].
Yuriko Uehara, Tomoya Shamoto, Hiroyuki Ogino, Yuri Yokoi, Shohei Hayashi

Gan To Kagaku Ryoho· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Group A Streptococcal Toxic Shock Syndrome after a Routine Gynecological Procedure.
Kei Ameda, Yoko Yamada, Yuriko Uehara, Tamami Ohno, Mari Hoya

Case Rep Obstet Gynecol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine Torsion in an Elderly Woman Associated with Leiomyoma and Continuously Elevating Muscle Enzymes: A Case Study and Review of Literature.
Hiroko Oda, Youko Yamada, Yuriko Uehara, Tamami Ohno, Mari Hoya

Case Rep Obstet Gynecol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
Chinami Makii, Yuji Ikeda, Katsutoshi Oda, Yuriko Uehara, Akira Nishijima

Gynecol Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.
Chinami Makii, Katsutoshi Oda, Yuji Ikeda, Kenbun Sone, Kosei Hasegawa, Yuriko Uehara

Oncotarget· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
Hiroe Nakamura, Kazunori Nagasaka, Kei Kawana, Ayumi Taguchi, Yuriko Uehara

BMC Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas.
Yuriko Uehara, Katsutoshi Oda, Yuji Ikeda, Takahiro Koso, Shingo Tsuji

PLoS One· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Kanako Inaba, Katsutoshi Oda, Yuji Ikeda, Kenbun Sone, Aki Miyasaka, Yuriko Uehara

Gynecol Oncol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer.
Aki Miyasaka, Katsutoshi Oda, Yuji Ikeda, Kenbun Sone, Tomohiko Fukuda, Yuriko Uehara

Gynecol Oncol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Aki Miyasaka, Katsutoshi Oda, Yuji Ikeda, Osamu Wada-Hiraike, Tomoko Kashiyama, Yuriko Uehara

BMC Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfated glycosaminoglycan-assisted receptor specificity of human fibroblast growth factor (FGF) 19 signaling in a mouse system is different from that in a human system.
Masao Nakamura, Yuriko Uehara, Masahiro Asada, Masashi Suzuki, Toru Imamura

J Biomol Screen· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.
Masao Nakamura, Yuriko Uehara, Masahiro Asada, Emi Honda, Naoko Nagai

J Biol Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c.
Masashi Suzuki, Yuriko Uehara, Kaori Motomura-Matsuzaka, Junko Oki, Yoshinori Koyama

Mol Endocrinol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis